Circulation: Population Health and Outcomes, an American Heart Association journal. RT/follows do not imply endorsement.
Joined September 2013
- Tweets9.4K
- Following5.2K
- Followers14.6K
- Likes3.6K
Pinned Tweet
For years, Circulation: Population Health and Outcomes has published research that helps shape cardiovascular health across communities and health systems. We're excited to announce Dhruv S. Kazi, MD, MSc, MS, (@kardiologykazi) as the next Editor-In-Chief.
Circ: PHO retweeted
🆕 Aging into Medicare Advantage at 65 is associated with ⬆️ improvements in care affordability and satisfaction.
Read more from the Center for Health Policy’s @AndrewOseran et al. in @CircOutcomes 🔗 bit.ly/4BSQ29N
ICYMI: Lp(a)FRONTIERS EXPANSION Study @kcferdmd et al
📍Presented at #ScientificSessions26
📝Simultaneous Publication in @CircOutcomes
Read More:
🔗ahajournals.org/doi/10.1161/… @AHAScience
Sim pub #ScientificSessions26
1st dedicated RCT of Lp(a)-lowering therapy in US Black/African American &Hispanic adults w/ Lp(a) >125 & ASCVD
Lp(a)FRONTIERS EXPANSION (n=422),monthly pelacarsen 80 mg led to an 86% placebo-adjusted Lp(a)reduction at week 52 & was well tolerated
Circ: PHO retweeted
This trial demonstrates the feasibility of recruiting and retaining individuals typically underrepresented in cardiovascular clinical trials - Black and Hispanic individuals, and women. This study raises the bar and shows us what we should expect in clinical trials.
Don't miss the accompanying Editorial by @hsbhatia:
Lp(a)FRONTIERS EXPANSION: Raising the Bar for Cardiovascular Clinical Trials #ScientificSessions26
🔗ahajournals.org/doi/10.1161/…
@AHAScience @kardiologykazi @iamritu @kcferdmd
ICYMI: 📍Featured Science Presentation @ #ScientificSessions26 | Simultaneous Publication in @CircOutcomes
The Lp(a)FRONTIERS EXPANSION Study
@kcferdmd et al
🔗ahajournals.org/doi/10.1161/…
Sim pub #ScientificSessions26
1st dedicated RCT of Lp(a)-lowering therapy in US Black/African American &Hispanic adults w/ Lp(a) >125 & ASCVD
Lp(a)FRONTIERS EXPANSION (n=422),monthly pelacarsen 80 mg led to an 86% placebo-adjusted Lp(a)reduction at week 52 & was well tolerated
Don't miss the accompanying Editorial by @hsbhatia:
Lp(a)FRONTIERS EXPANSION: Raising the Bar for Cardiovascular Clinical Trials #ScientificSessions26
🔗ahajournals.org/doi/10.1161/…
@AHAScience @kardiologykazi @iamritu @kcferdmd
Sim pub #ScientificSessions26
1st dedicated RCT of Lp(a)-lowering therapy in US Black/African American &Hispanic adults w/ Lp(a) >125 & ASCVD
Lp(a)FRONTIERS EXPANSION (n=422),monthly pelacarsen 80 mg led to an 86% placebo-adjusted Lp(a)reduction at week 52 & was well tolerated
Sim pub #ScientificSessions26
1st dedicated RCT of Lp(a)-lowering therapy in US Black/African American &Hispanic adults w/ Lp(a) >125 & ASCVD
Lp(a)FRONTIERS EXPANSION (n=422),monthly pelacarsen 80 mg led to an 86% placebo-adjusted Lp(a)reduction at week 52 & was well tolerated
🔗ahajournals.org/doi/10.1161/…
📌Featured Science Simultaneous Publication #ScientificSessions26
📝Article by @kcferdmd @FaRodriguezMD @DrMichaelShapir et al
@ducciobaldari @WFCardiology @TulaneMedicine @iamritu @AHAScience @kardiologykazi @bnallamo
📌Sim Pub with #ScientificSessions26
Sleep consistency matters more than sleep quantity?
🔗ahajournals.org/doi/10.1161/…
Read More ⬇️
In 10362 @AllofUsResearch Ppts w/ @Fitbit data, each 1-SD (29-min) rise in night-to-night sleep duration variability linked to 24% higher composite CVD risk (HR 1.24) HR for HF (1.32) HTN(1.6) DM2 (1.20)
Mean sleep duration was not
@UMmedschool @umms @BostonChildrens
@harvardmed
1
51
📌Sim Pub with #ScientificSessions26
Can quality improvement programs result in improved survival among single ventricle infants?
🔗ahajournals.org/doi/10.1161/…
Read more⬇️ (1/3🧵)
1
1
163
New study from 77 centers of 5,495 infants w/ this condition showed enrollment in the NPC-QIC resulted improved interstage survival b/w stage 1&2 surgical palliations from 90.5% to 94.8% & remained at this level for nearly a decade (2016-2025)
(🧵2/3)
1
1
65
📌Sim Pub with #ScientificSessions26
Cross-sectional study representing 147.3 million U.S adults (NHANES, 2015-2020) finds that among those recommended for lipid-lowering Rx (LLT) by guidelines, 12.8% use supplements instead ~4.2 million folks.
Read more ⬇️
~ 1/5 on LLT take supplements even though guideline advises against them
Read Online Here: 🔗ahajournals.org/doi/10.1161/…
@s_mangalesh
@pagingdrquds
@AnnMarieNavar
1
62
📌Sim pub #ScientificSessions26
Qualitative study creates #ACHD Care🎡 of 6 interdependent categories that shape care and emphasizes system structure, education, and support.
Read more⤵️
Novel findings: parents’ limited English sometimes supported patient engagement; caregiver support can build or limit independence. To improve care, target access to ACHD clinics, hand-offs & education
🔗ahajournals.org/doi/10.1161/…
📝Article by @AnuAgarwalMD @MegumiOkumura et al
Our Journals work together to rigorously and rapidly review essential research for simultaneous publication during #ScientificSessions26
The result? Nearly 44 peer-reviewed studies published across 4 journals.
Check out the latest at ahajournals.org/AHASessions
Circ: PHO retweeted
📌Sim Pub w/ #ScientificSessions26:
Can digital health accelerate GDMT optimization?
Randomized ENGAGE-HF trial shows improved #GDMT optimization at 90 days:
83.7% vs 74.0% (P=0.010)
Greater uptake of MRAs & SGLT2 inhibitors
A promising approach to post-discharge HF care
Our Journals work together to rigorously and rapidly review essential research for simultaneous publication during #ScientificSessions26
The result? Nearly 44 peer-reviewed studies published across 4 journals.
Check out the latest at ahajournals.org/AHASessions
1
258
Circ: PHO retweeted
In a world of AI and LLMs, does great writing still matter? Absolutely. Hear from a Nobel Laureate and top medical journal editors on developing communication skills that drive impact.
📅 Nov. 8 | 🕜 3:15-4:30 PM CT | 📍 S100A
Add it to your #ScientificSessions26 schedule
